HK1110200A1 - Remedy for hyperlipemia - Google Patents

Remedy for hyperlipemia

Info

Publication number
HK1110200A1
HK1110200A1 HK08100666.5A HK08100666A HK1110200A1 HK 1110200 A1 HK1110200 A1 HK 1110200A1 HK 08100666 A HK08100666 A HK 08100666A HK 1110200 A1 HK1110200 A1 HK 1110200A1
Authority
HK
Hong Kong
Prior art keywords
hyperlipemia
remedy
pitavastatin
ezetimibe
hypercholesterolemia
Prior art date
Application number
HK08100666.5A
Other languages
English (en)
Inventor
Taro Aoki
Hiroyuki Yamazaki
Takashi Maejima
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35944235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1110200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Publication of HK1110200A1 publication Critical patent/HK1110200A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08100666.5A 2004-08-31 2008-01-18 Remedy for hyperlipemia HK1110200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60552504P 2004-08-31 2004-08-31
US10/997,878 US20060046996A1 (en) 2004-08-31 2004-11-29 Method for treating hyperlipidemia
PCT/JP2005/015756 WO2006025378A1 (ja) 2004-08-31 2005-08-30 高脂血症治療剤

Publications (1)

Publication Number Publication Date
HK1110200A1 true HK1110200A1 (en) 2008-07-11

Family

ID=35944235

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100666.5A HK1110200A1 (en) 2004-08-31 2008-01-18 Remedy for hyperlipemia

Country Status (13)

Country Link
US (2) US20060046996A1 (ja)
EP (1) EP1785137B1 (ja)
JP (1) JP4886516B2 (ja)
KR (1) KR101244508B1 (ja)
CN (1) CN101010080B (ja)
AT (1) ATE489093T1 (ja)
CY (1) CY1111150T1 (ja)
DE (1) DE602005024981D1 (ja)
ES (1) ES2354366T3 (ja)
HK (1) HK1110200A1 (ja)
PL (1) PL1785137T3 (ja)
PT (1) PT1785137E (ja)
WO (1) WO2006025378A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20060276486A1 (en) * 2003-04-17 2006-12-07 Kowa Co., Ktd. Lklf/klf2 gene expression promoter
US7871998B2 (en) * 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US20130023513A1 (en) * 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
JPWO2020178878A1 (ja) * 2019-03-01 2020-09-10
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854259A (en) * 1987-08-20 1998-12-29 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2377526T3 (es) * 2005-01-10 2012-03-28 Cortendo Ab (Publ) 2S,4R ketoconazol para el tratamiento de la diabetes, el síndrome metabólico y otras afecciones

Also Published As

Publication number Publication date
JP4886516B2 (ja) 2012-02-29
US20060046996A1 (en) 2006-03-02
JPWO2006025378A1 (ja) 2008-05-08
US7459447B2 (en) 2008-12-02
PT1785137E (pt) 2010-12-23
CY1111150T1 (el) 2015-06-11
KR20070047766A (ko) 2007-05-07
EP1785137A1 (en) 2007-05-16
EP1785137A4 (en) 2007-12-19
DE602005024981D1 (de) 2011-01-05
EP1785137B1 (en) 2010-11-24
WO2006025378A1 (ja) 2006-03-09
ES2354366T3 (es) 2011-03-14
PL1785137T3 (pl) 2011-04-29
US20070032467A1 (en) 2007-02-08
CN101010080A (zh) 2007-08-01
ATE489093T1 (de) 2010-12-15
KR101244508B1 (ko) 2013-03-18
CN101010080B (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
HK1110200A1 (en) Remedy for hyperlipemia
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
CY2019030I1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
AU2003251563A1 (en) Implatable or insertable medical devices for controlled delivery of a therapeutic agent
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
DE60007592D1 (de) Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
WO2005044192A3 (en) Triazole compounds and uses related thereto
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
AU2002366355A1 (en) SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
HK1137142A1 (en) Drug for treatment of influenza
ATE360633T1 (de) N-substituierte hydromorphone und ihre anwendung
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EP1753425A4 (en) THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
ZA200609337B (en) Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
EP1796665A4 (en) COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
AU2003210659A1 (en) Combination therapy for treatment of hiv infection
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
ATE469642T1 (de) Vorbeugungs- oder heilmittel gegen endometriose

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210827